![Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma - ScienceDirect Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2531137920301139-gr3.jpg)
Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma - ScienceDirect
![del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma - ScienceDirect del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497121004584-grabsf1.jpg)
del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma - ScienceDirect
![Expression of interleukin-32 in bone marrow of patients with myeloma and its prognostic significance Expression of interleukin-32 in bone marrow of patients with myeloma and its prognostic significance](https://f6publishing.blob.core.windows.net/0e9eaf16-088a-4ffb-9ed9-4c6aa1a3e465/WJCC-7-4234-g002.png)
Expression of interleukin-32 in bone marrow of patients with myeloma and its prognostic significance
Outcome and survival of myeloma patients diagnosed 2008–2015. Real-world data on 4904 patients from the Swedish Myeloma Registry | Haematologica
![Progression-free and overall survival for high-risk patients with relapsed or refractory multiple myeloma (RRMM) who received carfilzomib-based regimens Progression-free and overall survival for high-risk patients with relapsed or refractory multiple myeloma (RRMM) who received carfilzomib-based regimens](https://s3.amazonaws.com/HMP/hmp_ln/imported/inline-images/Screen%20Shot%202018-10-11%20at%2010.04.49%20AM.png)
Progression-free and overall survival for high-risk patients with relapsed or refractory multiple myeloma (RRMM) who received carfilzomib-based regimens
![The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study | Atlantis Press The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study | Atlantis Press](https://www.atlantis-press.com/assets/articles/CHI-1-4-220/CHI-1-4-220-g005.png)
The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study | Atlantis Press
![Figure 1 from Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. | Semantic Scholar Figure 1 from Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/cd5c45b45e2148738cf5049d64e808e18e247c9f/3-Figure1-1.png)
Figure 1 from Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. | Semantic Scholar
![Mayo Clinic Rochester Publishes Updated Multiple Myeloma Survival Rates! - Multiple Myeloma - Survival Rate Statistics by Hospital Mayo Clinic Rochester Publishes Updated Multiple Myeloma Survival Rates! - Multiple Myeloma - Survival Rate Statistics by Hospital](http://myelomasurvival.com/uploads/3/4/4/8/34484049/mayoos-and-ss-tables_orig.png)
Mayo Clinic Rochester Publishes Updated Multiple Myeloma Survival Rates! - Multiple Myeloma - Survival Rate Statistics by Hospital
![Frontiers | Staging System to Predict the Risk of Relapse in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Frontiers | Staging System to Predict the Risk of Relapse in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation](https://www.frontiersin.org/files/Articles/459583/fonc-09-00633-HTML/image_m/fonc-09-00633-g001.jpg)
Frontiers | Staging System to Predict the Risk of Relapse in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
![The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial - The The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial - The](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2f9746ff-a56a-4d1f-9fa7-5e6b9f11a6ee/gr1_lrg.jpg)
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial - The
![Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience | Cancer Communications | Full Text Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience | Cancer Communications | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs40880-019-0395-3/MediaObjects/40880_2019_395_Fig1_HTML.png)
Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience | Cancer Communications | Full Text
![Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population - Clinical Lymphoma, Myeloma and Leukemia Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population - Clinical Lymphoma, Myeloma and Leukemia](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/4ce3aa2f-4df9-41a0-a9ab-b54e1e6e88ec/gr1.jpg)
Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population - Clinical Lymphoma, Myeloma and Leukemia
![Cureus | Increased Risk of Second Primary Malignancy and Mortality at ten Years After Stem Cell Transplant for Multiple Myeloma: An Analysis of 14,532 Patients Cureus | Increased Risk of Second Primary Malignancy and Mortality at ten Years After Stem Cell Transplant for Multiple Myeloma: An Analysis of 14,532 Patients](https://assets.cureus.com/uploads/figure/file/224839/lightbox_78138260c60611eb84f3550021c121c7-IFM2009.png)
Cureus | Increased Risk of Second Primary Malignancy and Mortality at ten Years After Stem Cell Transplant for Multiple Myeloma: An Analysis of 14,532 Patients
Outcome and survival of myeloma patients diagnosed 2008–2015. Real-world data on 4904 patients from the Swedish Myeloma Registry | Haematologica
Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011–2019 oncology clinic electronic he
![Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes - Landgren - 2017 - Journal of Internal Medicine - Wiley Online Library Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes - Landgren - 2017 - Journal of Internal Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/17df36d0-12e8-4dcb-b0d6-d53109c5fad0/joim12590-fig-0001-m.jpg)